Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Non-Current Deffered Revenue (2023 - 2026)

Beta Bionics' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $3.4 million for Q1 2026.

  • On a quarterly basis, Non-Current Deffered Revenue rose 43.78% to $3.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.4 million, a 43.78% increase, with the full-year FY2025 number at $3.3 million, up 77.26% from a year prior.
  • Non-Current Deffered Revenue hit $3.4 million in Q1 2026 for Beta Bionics, up from $3.3 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for BBNX hit a ceiling of $3.4 million in Q1 2026 and a floor of $255000.0 in Q4 2023.
  • Historically, Non-Current Deffered Revenue has averaged $2.4 million across 4 years, with a median of $2.7 million in 2025.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 629.41% in 2024 and later soared 43.78% in 2026.
  • Tracing BBNX's Non-Current Deffered Revenue over 4 years: stood at $255000.0 in 2023, then soared by 629.41% to $1.9 million in 2024, then soared by 77.26% to $3.3 million in 2025, then grew by 1.61% to $3.4 million in 2026.
  • Business Quant data shows Non-Current Deffered Revenue for BBNX at $3.4 million in Q1 2026, $3.3 million in Q4 2025, and $3.0 million in Q3 2025.